Cannabis Index Rise 2.99%: Brace for a Marijuana Boom in 2022

A small-cap cannabis stock is the better buy if investors are preparing for a marijuana boom in 2022.

| More on:
Cannabis stocks have fallen.

Should investors in the cannabis space prepare for a marijuana boom in 2022? On November 12, 2021, the Canadian Cannabis LP Index rose 2.99%. Industry leaders Canopy Growth, Aurora Cannabis, and Cronos Group led the charge with gains of 12.77%, 12.49%, and 10.39%, respectively.

Others, like Hexo and OrganiGram Holdings (TSX:OGI)(NASDAQ:OGI), gained more than 6%. However, not all leading names are winning investments in 2021. Hexo and Canopy Growth are losing by 52.25% and 38.83%, respectively, year to date. Aurora Cannabis is up by only 1.13%. OrganiGram is the high-flying growth stock with its 76.33% gain.

While it’s been extremely challenging for weed stocks in the last 12 months, the index’s 57% advance in September is encouraging. Likewise, the latest development in U.S. Congress seems to suggest the federal legalization of marijuana might come sooner than later.

New draft legislation

On November 5, 2021, reports came out that Republican congresswoman Nancy Mace submitted draft legislation titled the States Reform Act. The measure is circulating among stakeholders for their feedback. While it’s temporary, the filing of the final draft or version could be in late November.

The Democrats want to pass large-scale marijuana bills, which the other side opposes, whether in the House or the Senate. Somehow, the proposed measure of Rep. Mace could be the compromise that conservatives and progressives could agree on.

De-scheduling of marijuana

The congresswoman’s draft legislation aims to de-schedule marijuana federally and create a regulatory scheme. It also ensures that no existing markets would be unduly burdened nor undermined by new rules. The proposed federal de-scheduling means the treatment of cannabis would be the same as the treatment for alcohol.

Other draft details include tasking the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau (TTB) to be the chief regulator for marijuana concerning interstate commerce. It limits the regulatory authority of the Food and Drug Administration (FDA) too in that it would relinquish control over cannabis like with alcohol.

The FDA would have a say on prescribing serving sizes of medical cannabis and approval or regulation of marijuana-based pharmaceuticals. However, the agency could not ban the use of cannabis or its derivatives in non-drug applications.

If approved, Mace’s bill would incorporate existing state-licensed cannabis operators into the federal scheme. Last, the Bureau of Labor Statistics (BLS) must issue a report to Congress on the marijuana industry.

Top pick

If you were to invest in cannabis today, OrganiGram is the top pick for its consistent performance. At $2.98 per share, the trailing one-year price return is 104.11%. Based on market analysts’ forecasts, the upside potential is 33.89% ($3.99). In Q3 fiscal 2021 (quarter ended May 31, 2021), net loss versus Q3 2020 reduced significantly by 96% to $4 million.

The $890.37 million licensed cannabis producer’s gross revenue climbed 31% to $29.1 million. OGI’s Chief Strategy Officer Paolo De Luca said, “The ongoing investment in our genetics and cultivation program has yielded some exciting new dried flower products.” The revitalized product portfolio and upcoming product launches are its competitive advantages for the near term.

The long wait could soon be over

A scaled-down measure with safeguards could be the key to the federal legalization of marijuana in the United States. The long wait could be over in early 2022.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool recommends HEXO Corp. and OrganiGram Holdings.

More on Cannabis Stocks

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Here’s Why it’s Not Too Late to Buy Cronos Group Stock

The optimism about U.S. federal marijuana legalization and its anticipation are potent bullish triggers for the Canadian cannabis industry.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock Is on a Tear: Is it a Good Buy Now? 

Canopy Growth (TSX:WEED) stock surged by 80% from news out of the U.S., but is enough there without the news…

Read more »

Marijuana plant and cannabis oil bottles isolated
Cannabis Stocks

Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030

Quality cannabis stocks such as Green Thumb and Cresco Labs are positioned to deliver outsized gains to shareholders in 2024…

Read more »